Physicians' Academy for Cardiovascular Education

LDL-c & PCSK9 inhibition in high CV risk patients

Report on expert meeting on LDL-c & PCSK9 inhibition in high CV risk patients

Challenges for screening and treatment of FH patients in clinical cardiology

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.

How are the guidelines for progressive CAD guiding us in clinical practice?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Cholesterol guidelines in need of major changes?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

Are very low LDL-c levels safe?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

LDL-c as target in cardiology: The road towards lower targets

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.